Maravai LifeSciences Expands Its Intellectual Property Portfolio
Maravai LifeSciences (NASDAQ: MRVI) announced a new patent (No. 10,913,768) issued for its CleanCap technology, enhancing mRNA vaccine and therapeutic development. This patent represents the third for CleanCap, which improves the co-transcriptional capping process in synthetic mRNA production. The technology streamlines manufacturing, decreases costs, and accelerates the production of mRNA, critical for personalized cancer therapies and rapid vaccine responses. Maravai continues to lead in providing essential products for drug therapies, diagnostics, and vaccine research.
- Issuance of third U.S. patent for CleanCap technology enhances competitive position.
- Improved capping process streamlines mRNA manufacturing, reducing time and costs.
- Technology supports rapid development of personalized cancer therapeutics and pandemic responses.
- None.
Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that the United States Patent and Trademark Office has issued a new patent, United States Patent No. 10,913,768, to the company’s TriLink Biotechnologies subsidiary.
The patent covers advancements in TriLink’s CleanCap® technology for the co-transcriptional capping of messenger RNAs (mRNAs). This patent is the third U.S. patent that has issued to the company related to the CleanCap technology. Capping is an important step in the production of synthetic mRNA, which is used to develop nucleic acid vaccines and therapeutics that deliver instructions to human cells to produce proteins that may prevent or correct disease.
The technology described by United States Patent No. 10,913,768 facilitates the production of mRNAs and provides a significant improvement over legacy co-transcriptional capping methods.
“Capping is a critical process in creating viable mRNA constructs that remain biologically active without eliciting immune responses,” explains Mike Houston, Ph.D., Chief Scientific Officer of Maravai. “By changing the capping approach and streamlining the manufacturing workflow, we deliver a novel solution, whether customers purchase CleanCap in bulk for their own mRNA development programs or utilize mRNA synthesized by TriLink BioTechnologies that already incorporates this novel capping technology.”
CleanCap overcomes many drawbacks of existing approaches, enabling highly-efficient, reproducible production of capped mRNA. CleanCap technology allows capping to occur in a single reaction, streamlining the manufacturing of mRNA at large scales. Reduced manufacturing time is critical for a number of emerging applications, such as the development of personalized cancer therapeutics and during rapid vaccine responses to pandemics. CleanCap also reduces the cost of mRNA manufacturing, further accelerating the adoption of new mRNA therapeutics.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
About TriLink BioTechnologies
TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap mRNA capping technology. TriLink continues to expand its cGMP and general manufacturing capacity at its new global headquarters to support mRNA, oligonucleotide & DNA plasmid therapeutic, vaccine and diagnostic customers. www.trilinkbiotech.com
Forward-looking Statements
This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the advantages of CleanCap technology, the cost of mRNA manufacturing, and acceleration of new mRNA vaccines and therapeutics, constitute forward-looking statements identified by words like “expect,” “may,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation and uncertainties related to continued validation of the safety and effectiveness of our technology, new scientific developments and competition from other products. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Maravai’s Form S-1 Prospectus on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
FAQ
What is the significance of the new patent issued to Maravai LifeSciences on February 10, 2021?
How does CleanCap technology benefit mRNA manufacturing?
What recent advancements has Maravai made in mRNA technology?
What are the potential applications of Maravai's CleanCap technology?
